Pharmaceutical

Eton acquires US rights to neonatal diabetes treatment from AMMTeK

Eton has acquired the rights in the US to Amglidia for neonatal diabetes mellitus, from French biotechnology company AMMTeK.

Nov 27, 2024 - 06:00
Eton acquires US rights to neonatal diabetes treatment from AMMTeK
Eton has acquired the rights in the US to Amglidia for neonatal diabetes mellitus, from French biotechnology company AMMTeK.
Read the original article

Tags:

Previous Article

NHS rolls out monoclonal antibody treatment for rare bone disease  

Next Article

Roche’s tiragolumab flops in another Phase III lung cancer trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Scientists have mapped the human brain in unprecedented detail. They’re just getting started

STAT+: Scientists have mapped the human brain in unprec...

Oct 12, 2023

Inflation reduction act boosts biologic drug venture financing over small molecules

Inflation reduction act boosts biologic drug venture fi...

Jun 27, 2023

FDA rejects Lykos MDMA therapy, asks for another Phase III trial

FDA rejects Lykos MDMA therapy, asks for another Phase ...

Aug 13, 2024